BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 833 Shares

Key Points

• Troy Wichterman, CFO of BioLife Solutions, sold 833 shares at an average price of $27.36, resulting in a total transaction value of $22,790.88, and decreased his ownership by 0.45% to 183,353 shares.
• BioLife Solutions reported a loss of ($0.33) earnings per share, missing the consensus estimate by a significant margin, although revenue for the quarter was $25.42 million, exceeding expectations.
• Equity analysts have mixed opinions on BioLife Solutions, with ratings ranging from "buy" to "sell", leading to a current consensus rating of "Moderate Buy" with an average target price of $31.29.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 833 shares of the firm's stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $27.36, for a total transaction of $22,790.88. Following the sale, the chief financial officer owned 183,353 shares in the company, valued at $5,016,538.08. This trade represents a 0.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Troy Wichterman also recently made the following trade(s):

• On Thursday, September 11th, Troy Wichterman sold 1,032 shares of BioLife Solutions stock. The stock was sold at an average price of $26.83, for a total transaction of $27,688.56.
• On Tuesday, August 26th, Troy Wichterman sold 590 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total transaction of $15,009.60.

BioLife Solutions Stock Up 0.9%

Shares of NASDAQ:BLFS traded up $0.24 during midday trading on Tuesday, hitting $27.66. The stock had a trading volume of 346,859 shares, compared to its average volume of 465,156. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.55. The business's 50-day simple moving average is $25.21 and its 200-day simple moving average is $23.33. The company has a market cap of $1.32 billion, a P/E ratio of -230.48 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BLFS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Stephens initiated coverage on shares of BioLife Solutions in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price for the company. Zacks Research downgraded BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.29.

Institutional Trading of BioLife Solutions

Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming boosted its holdings in BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares during the last quarter. US Bancorp DE raised its position in shares of BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,528 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 441 shares during the period. GAMMA Investing LLC raised its position in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the period. Finally, Strs Ohio acquired a new position in shares of BioLife Solutions during the first quarter worth approximately $153,000. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.